Serine-arginine protein kinase 1 is associated with hepatocellular carcinoma progression and poor patient survival
- 150 Downloads
The pre-mRNA splicing regulator serine-arginine protein kinase 1 (SRPK1) promotes cancer development and various pathophysiological processes. However, the clinical relevance of SRPK1 in hepatocellular carcinoma (HCC) is not clear. This study investigates the expression and prognostic value of SRPK1 in HCC. We found that SRPK1 expression was significantly upregulated at the mRNA and protein level in all HCC cell lines or HCC tissue samples compared with the hepatic cell line or matched noncancerous tissue samples, respectively. Higher SRPK1 expression significantly correlated with clinical staging (p = 0.031), survival time (p = 0.004), and gender (p = 0.011) of HCC patients. Together, our study showed that SRPK1 is overexpressed in HCC and may be a promising indicator of prognosis for HCC patients.
KeywordsSRPK1 Hepatocellular carcinoma Prognosis
This work was supported by the Science and Technology Department of Guangzhou (No. 2014 J4100063), National Science Foundation of China (No. 81101317), and Science and Technology Planning Project of Guangdong Province, China (No. 2013B021800040)
GS, JZ, HJ, and WFX devised the study. JZ, HJ, YZJ, XYT, and PYL selected participants, oversaw diagnostic evaluations, and directed YJ, XJ, and PYL studies and analyses. HYJ and XWY performed the statistical analyses. GS wrote the manuscript and all authors participated in reviewing and editing the manuscript.
- 6.Plasencia C, Martínez-Balibrea E, Martinez-Cardús A, Quinn DI, Abad A, Neamati N. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol. 2006;1:225–35.Google Scholar
- 7.Odunsi K, Mhawech-Fauceglia P, Andrews C, Beck A, Amuwo O, Lele S, et al. Elevated expression of the serine-arginine protein kinase 1 gene in ovarian cancer and its role in cisplatin cytotoxicity in vitro. PLoS One. 2012;7(12):e51030. doi: 10.1371/journal.pone.0051030.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, et al. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem. 2010;285(8):5532–40. doi: 10.1074/jbc.M109.074930.CrossRefPubMedGoogle Scholar
- 10.Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin. 2002;2005(55):74–108.Google Scholar
- 11.Luca Faloppi B, Mario Scartozzi A, Elena Maccaroni B, Marzia Di Pietro Paolo C, Rossana Berardi A, Michela Del Prete A, Stefano C. Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-taylored therapeutic options. Cancer Treat Rev 2011;(37):169–177.Google Scholar
- 19.Baig S. Gender disparity in infections of Hepatitis B virus. S J Coll Physicians Surg Pak. 2009;19(9):598–600.Google Scholar
- 24.Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002;14:4123–31.Google Scholar